ADMA BIOLOGICS, INC.
For the period ended Jun 30, 2025. Filed Aug 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
(a) Sales of Unregistered Securities and Use of Proceeds
None.
(c) Repurchases of Securities
Index
The table below reflects shares of common stock we repurchased during the second quarter of 2025.
| For the Month Ended | Total Number of Shares Purchased | Average Price Paid Per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs(1) | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs(2) |
|---|---|---|---|---|
| April 30, 2025 · - · $ · - · - · $ · - | ||||
| May 31, 2025 · - · $ · - · - · $ · - | ||||
| June 30, 2025 | 816,237 | $18.35 | 816,237 | $485,002,210 |
| Total | 816,237 | $18.35 | 816,237 | |
(1) Shares were repurchased pursuant to our share repurchase program publicly announced on May 5, 2025.
(2) There is no expiration date for this share repurchase program. The authorization to repurchase shares will end when we have repurchased the maximum number of shares authorized, or if we have determined to terminate such program.
Item 3.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.